Durgical
EN
Open the app

When to think of an inherited endocrine syndrome: MEN1, MEN2 and their relatives

  • Diagnostic approach

Some hormone-making tumours run in families. Spotting them changes the order of surgery and protects relatives who can be tested and followed.

Updated

See it in 3D: Thyroid gland · Parathyroid glands · Left adrenal gland · Pancreas · Pituitary gland

What it is

Multiple endocrine neoplasia (MEN) syndromes are autosomal dominant conditions in which several endocrine glands develop tumours. MEN1 (MEN1 gene) combines hyperparathyroidism from several glands, pancreatic and duodenal neuroendocrine tumours (gastrinoma, insulinoma, non-functioning) and pituitary adenomas (most often prolactinoma). MEN2A (RET gene) combines medullary thyroid carcinoma in almost every carrier, phaeochromocytoma in about half and hyperparathyroidism in a minority. MEN2B (RET, usually M918T) brings an earlier and more aggressive medullary carcinoma, phaeochromocytoma, mucosal neuromas and a marfanoid build, but no hyperparathyroidism. Related syndromes include von Hippel–Lindau disease, neurofibromatosis type 1, succinate dehydrogenase (SDH)-related paragangliomas, MEN4 and Carney complex.

What to know

  • Triggers for genetic testing: primary hyperparathyroidism before about 30 or in several glands, a gastrinoma, any medullary thyroid carcinoma, any phaeochromocytoma or paraganglioma, two MEN-associated tumours, or an affected relative.
  • Calcitonin (with CEA) is the tumour marker of medullary thyroid carcinoma.
  • In MEN2, the RET variant sets the age for preventive thyroidectomy: in the highest-risk variant it is done in the first year of life.
  • Before any operation in a patient with MEN2 or medullary thyroid carcinoma, exclude phaeochromocytoma and remove it first.
  • MEN1 hyperparathyroidism involves several glands: removing one gland leads to recurrence, so subtotal or total parathyroidectomy is used.
  • MEN1 gastrinomas are usually multiple and small, in the duodenum.
  • Von Hippel–Lindau disease adds retinal and cerebellar haemangioblastomas, clear-cell kidney cancer and pancreatic cysts or tumours.

Step-by-step approach

  1. Recognise a trigger in the patient.
  2. Take a three-generation family history of endocrine tumours, kidney stones, ulcers, early sudden deaths and hypertension.
  3. Offer genetic counselling and testing (MEN1, RET, or a phaeochromocytoma–paraganglioma panel).
  4. Before any surgery, exclude phaeochromocytoma with metanephrines.
  5. If a variant is found, start an age-based surveillance programme for the tumours it predicts.
  6. Offer cascade testing to first-degree relatives; in RET carriers, plan preventive thyroidectomy by risk level.

The inherited endocrine tumour syndromes

SyndromeGeneMain tumoursTelltale clue
MEN1MEN1Parathyroid (several glands), pancreatic and duodenal neuroendocrine tumours, pituitary adenomasYoung patient with hyperparathyroidism plus ulcers (gastrinoma) or a prolactinoma
MEN2ARETMedullary thyroid carcinoma, phaeochromocytoma, parathyroidMedullary carcinoma with episodes of high blood pressure; itchy skin amyloidosis on the back
MEN2BRET (usually M918T)Early aggressive medullary carcinoma, phaeochromocytomaBumpy lips and tongue (mucosal neuromas), marfanoid build; no hyperparathyroidism
Von Hippel–LindauVHLPhaeochromocytoma, clear-cell kidney cancer, haemangioblastomas, pancreatic tumoursRetinal or cerebellar haemangioblastoma
Neurofibromatosis type 1NF1PhaeochromocytomaCafé-au-lait spots, neurofibromas
SDH-related paragangliomaSDHB, SDHD and othersParagangliomas, phaeochromocytomaHead and neck or abdominal paraganglioma; SDHB tumours more often malignant

Keys to the differential

  • Medullary thyroid carcinoma is not treated with radioiodine (C cells do not take up iodine); surgery is the treatment.
  • A relative who tests negative for the family's known variant can stop surveillance; one who tests positive needs lifelong follow-up.
  • Genetic results change the care of the whole family, so counselling comes before and after testing.

Next step / Initial management

  • Calcium and PTH, metanephrines, calcitonin, and prolactin or gastrin as the history suggests.
  • Genetic testing with counselling for every patient with a trigger.
  • Exclude phaeochromocytoma before thyroid, parathyroid or any other surgery.
  • Refer to endocrinology and clinical genetics every suspected or confirmed carrier and their family.

Common traps

  • Medullary thyroid carcinoma can be operated on straight away: an unrecognised phaeochromocytoma (MEN2) can cause a fatal hypertensive crisis during surgery, so metanephrines are measured first.
  • Removing a single parathyroid gland cures MEN1: MEN1 affects several parathyroid glands, so removing one leads to recurrence; subtotal or total parathyroidectomy is used.
  • A phaeochromocytoma is sporadic unless proven otherwise: a large share are hereditary, so every patient is offered genetic testing.
  • MEN2B includes hyperparathyroidism: MEN2B brings medullary carcinoma, phaeochromocytoma, mucosal neuromas and a marfanoid build, but no hyperparathyroidism.
  • Radioiodine treats medullary thyroid carcinoma: C cells do not take up iodine; surgery is the treatment.

Test yourself

Think of the answer, then tap the question to see it.

A 25-year-old has hyperparathyroidism with three enlarged glands and recurrent duodenal ulcers. What syndrome and which tumour explains the ulcers?

MEN1: multigland hyperparathyroidism with a gastrinoma (Zollinger–Ellison syndrome) driving the ulcers.

A patient with a new medullary thyroid carcinoma is booked for thyroidectomy. What must be done first, and why?

Measure metanephrines to exclude phaeochromocytoma (MEN2): operating with an unknown phaeochromocytoma can cause a fatal hypertensive crisis.

Why does a child who carries the high-risk RET variant have the thyroid removed before cancer appears?

Medullary carcinoma develops in almost every carrier, very early in the highest-risk variant; removing the thyroid before it spreads is curative.

Add to my cards (3)

Elsewhere in DurgiPedia

Connections

← All of endocrinology

Educational content; it does not replace a medical assessment and is not a clinical instruction. For confusion, persistent vomiting with diabetes, fainting or very low blood pressure in someone who takes or has stopped glucocorticoids, go to an emergency department at once.

Sources: Multiple Endocrine Neoplasia Type 1 (StatPearls (NCBI Bookshelf), 2023); Multiple Endocrine Neoplasia Type 2 (StatPearls (NCBI Bookshelf), 2026); Pheochromocytoma (StatPearls (NCBI Bookshelf), 2024).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.